Double maintains 9 strategies that include REGN - Regeneron Pharmaceuticals, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BAR | -0.04% | $1.16B | 0.1749% |
CMBS | -0.09% | $440.11M | 0.25% |
AAAU | 0.13% | $1.53B | 0.18% |
IAU | -0.13% | $48.28B | 0.25% |
TFLO | 0.15% | $6.90B | 0.15% |
SGOL | 0.17% | $5.37B | 0.17% |
GLD | 0.22% | $104.02B | 0.4% |
BNO | -0.27% | $97.13M | 1% |
STOT | -0.38% | $239.87M | 0.45% |
UDN | 0.43% | $146.24M | 0.78% |
USL | -0.43% | $43.35M | 0.85% |
OUNZ | 0.44% | $1.77B | 0.25% |
UUP | 0.46% | $156.34M | 0.77% |
OILK | 0.64% | $74.96M | 0.69% |
GOAU | 0.72% | $154.84M | 0.6% |
CTA | 0.75% | $1.09B | 0.76% |
USO | -0.76% | $1.20B | 0.6% |
IBTG | 0.81% | $1.95B | 0.07% |
IBTI | 0.85% | $1.04B | 0.07% |
USFR | 0.86% | $18.71B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 64.09% | $5.43B | 0.45% |
BBH | 62.51% | $337.72M | 0.35% |
FBT | 58.62% | $1.02B | 0.54% |
PBE | 57.06% | $223.42M | 0.58% |
XBI | 54.13% | $4.57B | 0.35% |
RSPH | 52.57% | $743.58M | 0.4% |
VHT | 51.93% | $15.53B | 0.09% |
FHLC | 51.51% | $2.47B | 0.084% |
IYH | 51.38% | $2.77B | 0.39% |
HYXF | 51.26% | $179.49M | 0.35% |
PINK | 50.82% | $131.84M | 0.5% |
FXH | 50.50% | $904.53M | 0.62% |
XLV | 50.22% | $34.81B | 0.09% |
PPH | 49.46% | $606.82M | 0.36% |
IHE | 48.85% | $574.16M | 0.39% |
IXJ | 48.71% | $3.82B | 0.41% |
XPH | 47.85% | $151.38M | 0.35% |
GNOM | 45.34% | $43.91M | 0.5% |
MOAT | 44.93% | $12.53B | 0.47% |
SCHD | 42.75% | $70.05B | 0.06% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -28.71% | $196.95M | 0.85% |
TAIL | -26.66% | $104.04M | 0.59% |
BTAL | -20.14% | $296.94M | 1.43% |
IVOL | -15.16% | $346.82M | 1.02% |
XHLF | -13.73% | $1.66B | 0.03% |
CLIP | -11.47% | $1.50B | 0.07% |
TBLL | -11.08% | $2.24B | 0.08% |
BIL | -10.48% | $43.88B | 0.1356% |
TPMN | -10.01% | $30.86M | 0.65% |
XONE | -9.50% | $639.76M | 0.03% |
GBIL | -8.71% | $6.18B | 0.12% |
BILZ | -7.38% | $840.57M | 0.14% |
AGZD | -7.14% | $111.95M | 0.23% |
FXY | -6.80% | $859.86M | 0.4% |
JMST | -6.39% | $3.97B | 0.18% |
BOXX | -6.31% | $6.64B | 0.19% |
SPTS | -5.18% | $5.79B | 0.03% |
BILS | -4.38% | $3.92B | 0.1356% |
FMF | -3.91% | $157.02M | 0.95% |
ULST | -3.66% | $667.74M | 0.2% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BIIB | 52.39% | $18.54B | -43.41% | 0.00% |
SNY | 45.33% | $117.49B | +2.12% | 4.59% |
MTD | 45.12% | $23.91B | -22.31% | 0.00% |
RVTY | 44.34% | $11.10B | -12.24% | 0.30% |
IQV | 43.25% | $26.66B | -27.59% | 0.00% |
ROIV | 43.02% | $7.55B | +2.49% | 0.00% |
COO | 41.38% | $13.72B | -24.98% | 0.00% |
LYB | 41.24% | $19.15B | -37.52% | 9.02% |
A | 41.01% | $32.98B | -13.94% | 0.84% |
KRYS | 40.67% | $3.76B | -24.84% | 0.00% |
GEHC | 40.44% | $32.57B | -9.11% | 0.18% |
PFE | 40.30% | $136.45B | -12.44% | 7.13% |
BRKR | 40.17% | $5.70B | -43.67% | 0.53% |
VRTX | 40.11% | $113.50B | -5.41% | 0.00% |
LFUS | 40.07% | $5.33B | -17.97% | 1.27% |
IOVA | 39.95% | $674.55M | -74.75% | 0.00% |
ARW | 39.83% | $6.44B | -1.31% | 0.00% |
MFA | 39.83% | $964.94M | -14.16% | 15.03% |
TMO | 39.73% | $147.32B | -31.43% | 0.42% |
IDYA | 39.72% | $1.92B | -41.19% | 0.00% |
Yahoo
Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index dropping 1.7% and
Yahoo
A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.
Yahoo
Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.
Yahoo
Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.
Yahoo
-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday. Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.
Yahoo
Lynozyfic’s global sales are projected to reach $707 million by 2031.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UNH | -<0.01% | $280.19B | -35.79% | 3.43% |
GALT | -0.05% | $151.27M | +2.58% | 0.00% |
SHLS | -0.06% | $879.34M | -23.55% | 0.00% |
HCI | -0.06% | $1.78B | +66.39% | 1.05% |
LFWD | 0.09% | $12.11M | -73.87% | 0.00% |
LEU | 0.13% | $2.95B | +315.04% | 0.00% |
MYRG | -0.16% | $2.59B | +19.47% | 0.00% |
AVD | -0.21% | $134.14M | -55.22% | 0.77% |
GEO | 0.31% | $3.40B | +87.32% | 0.00% |
EVGO | 0.34% | $606.44M | +121.57% | 0.00% |
PINC | 0.37% | $1.83B | +22.39% | 3.76% |
IMNN | 0.44% | $19.82M | +5.61% | 0.00% |
LNG | -0.48% | $52.34B | +46.48% | 0.82% |
FARO | 0.53% | $845.69M | +163.42% | 0.00% |
QBTS | 0.60% | $4.86B | +1,240.52% | 0.00% |
AGL | 0.61% | $869.30M | -68.84% | 0.00% |
VHC | -0.66% | $36.03M | +76.35% | 0.00% |
AU | 0.68% | $24.34B | +111.51% | 2.16% |
DRD | -0.68% | $1.23B | +69.64% | 1.98% |
EGO | 0.68% | $4.35B | +42.59% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RRGB | -27.67% | $92.40M | -30.99% | 0.00% |
UUU | -18.11% | $7.19M | +94.38% | 0.00% |
ROOT | -11.24% | $2.17B | +208.61% | 0.00% |
MO | -7.45% | $99.37B | +31.67% | 6.86% |
NEXT | -7.13% | $2.19B | +10.10% | 0.00% |
CARV | -6.88% | $8.54M | +3.12% | 0.00% |
MKTX | -6.75% | $8.38B | +14.26% | 1.35% |
FMTO | -6.60% | $4.80K | -99.93% | 0.00% |
PULM | -6.56% | $29.80M | +325.00% | 0.00% |
RLX | -5.98% | $2.01B | +22.78% | 0.46% |
SUP | -5.49% | $9.54M | -90.31% | 0.00% |
USM | -5.14% | $5.09B | +12.61% | 0.00% |
TZOO | -5.12% | $138.69M | +59.85% | 0.00% |
ATEC | -5.07% | $1.59B | +4.53% | 0.00% |
OR | -4.49% | $4.90B | +58.08% | 0.71% |
TDS | -4.47% | $3.80B | +72.41% | 0.48% |
UVV | -4.38% | $1.46B | +26.52% | 5.43% |
AIFU | -4.02% | $3.58B | +6.56% | 0.00% |
TH | -3.99% | $693.57M | -12.20% | 0.00% |
NGVC | -3.80% | $943.72M | +95.90% | 1.12% |
Current Value
$508.511 Year Return
Current Value
$508.511 Year Return